RUGGIERO, DONATELLA
RUGGIERO, DONATELLA
Dipartimento di Medicina Sperimentale
A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use
2025 Zinzi, A.; Gaio, M.; Ruggiero, D.; Riccardi, C.; Cagnotta, C.; Pentella, C.; Capuano, A.; Rafaniello, C.
COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database
2023 Ruggiero, R.; Donniacuo, M.; Mascolo, A.; Gaio, M.; Cappetta, D.; Rafaniello, C.; Docimo, G.; Riccardi, C.; Izzo, I.; Ruggiero, D.; Paolisso, G.; Rossi, F.; De Angelis, A.; Capuano, A.
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
2023 Ruggiero, R.; Di Napoli, R.; Balzano, N.; Ruggiero, D.; Riccardi, C.; Anatriello, A.; Cantone, A.; Sportiello, L.; Rossi, F.; Capuano, A.
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System
2025 Balzano, N.; Mascolo, A.; Ruggiero, D.; Rafaniello, C.; Paolisso, G.; Rossi, F.; Capuano, A.
Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database
2024 Mascolo, A.; Zinzi, A.; Gaio, M.; Ruggiero, D.; Scavone, C.; Rossi, F.; Capuano, A.
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
2023 Mascolo, A.; Rafaniello, C.; di Mauro, G.; Ruggiero, D.; Campitiello, M. R.; Donniacuo, M.; Berrino, P. M.; Rossi, F.; Paolisso, G.; Capuano, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use | 1-gen-2025 | Zinzi, A.; Gaio, M.; Ruggiero, D.; Riccardi, C.; Cagnotta, C.; Pentella, C.; Capuano, A.; Rafaniello, C. | |
| COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database | 1-gen-2023 | Ruggiero, R.; Donniacuo, M.; Mascolo, A.; Gaio, M.; Cappetta, D.; Rafaniello, C.; Docimo, G.; Riccardi, C.; Izzo, I.; Ruggiero, D.; Paolisso, G.; Rossi, F.; De Angelis, A.; Capuano, A. | |
| Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management | 1-gen-2023 | Ruggiero, R.; Di Napoli, R.; Balzano, N.; Ruggiero, D.; Riccardi, C.; Anatriello, A.; Cantone, A.; Sportiello, L.; Rossi, F.; Capuano, A. | |
| Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System | 1-gen-2025 | Balzano, N.; Mascolo, A.; Ruggiero, D.; Rafaniello, C.; Paolisso, G.; Rossi, F.; Capuano, A. | |
| Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database | 1-gen-2024 | Mascolo, A.; Zinzi, A.; Gaio, M.; Ruggiero, D.; Scavone, C.; Rossi, F.; Capuano, A. | |
| Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis | 1-gen-2023 | Mascolo, A.; Rafaniello, C.; di Mauro, G.; Ruggiero, D.; Campitiello, M. R.; Donniacuo, M.; Berrino, P. M.; Rossi, F.; Paolisso, G.; Capuano, A. |